NCT06720636 Ultralong-segment Barrett's Esophagus: Towards a Capsule-sponge Surveillance Strategy
| NCT ID | NCT06720636 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Erasmus Medical Center |
| Condition | Barrett Esophagus |
| Study Type | INTERVENTIONAL |
| Enrollment | 137 participants |
| Start Date | 2025-02-03 |
| Primary Completion | 2027-09 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 137 participants in total. It began in 2025-02-03 with a primary completion date of 2027-09.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to evaluate the Endosign capsule sponge test as a novel surveillance method in patients with an ultralong-segment Barrett's esophagus.
Eligibility Criteria
Inclusion Criteria: * Any participant 18 years and above, with ultralong-segment Barrett's esophagus and clinically fit for an endoscopy * Ability to provide informed consent Exclusion Criteria: * Individuals with a diagnosis of an oro-pharynx, esophageal or gastro-esophageal tumor (T2 staging and above), or symptoms of dysphagia * Esophageal varices or stricture requiring dilatation of the esophagus * Individuals who have had a cerebrovascular event \< 6 months prior where their swallowing has been affected * Patients who have had previous treatments such as Photodynamic therapy (PDT), Radiofrequency ablation (RFA) or Argon Plasma Coagulation (APC) for dysplastic Barrett's esophagus * Participants who are unable to provide informed consent * Participants under age 18 years
Contact & Investigator
Judith Honing, MSc, PhD
PRINCIPAL INVESTIGATOR
Erasmus Medical Center
Frequently Asked Questions
Who can join the NCT06720636 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Barrett Esophagus. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06720636 currently recruiting?
Yes, NCT06720636 is actively recruiting participants. Contact the research team at a.degroen@erasmusmc.nl for enrollment information.
Where is the NCT06720636 trial being conducted?
This trial is being conducted at Rotterdam, Netherlands.
Who is sponsoring the NCT06720636 clinical trial?
NCT06720636 is sponsored by Erasmus Medical Center. The principal investigator is Judith Honing, MSc, PhD at Erasmus Medical Center. The trial plans to enroll 137 participants.